I’m on the sidelines waiting for the post-lockup sales and the speculative fervor from the recent journal publication to work through. The best time to buy ALNY may be about six months from now --after one of ALNY’s competitors (Sirna or Acuity) releases phase-1 clinical data in AMD. ALNY’s guidance says that, by then, they will have entered into a second partnership in a different disease area.
Market Data 
Markets 
AI
